2004
DOI: 10.1001/archpsyc.61.11.1136
|View full text |Cite
|
Sign up to set email alerts
|

Cognitive Enhancers as Adjuncts to Psychotherapy

Abstract: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
305
3
1

Year Published

2005
2005
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 1,016 publications
(314 citation statements)
references
References 47 publications
(85 reference statements)
5
305
3
1
Order By: Relevance
“…Exposure-based psychotherapy of phobia is thought to rely on extinction of fear responses (Ressler et al 2004;McNally, 2007), a learning mechanism that has been shown to be significantly delayed in phobias and other anxiety disorders. In animals, the important role of sleep for extinction learning is well established.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Exposure-based psychotherapy of phobia is thought to rely on extinction of fear responses (Ressler et al 2004;McNally, 2007), a learning mechanism that has been shown to be significantly delayed in phobias and other anxiety disorders. In animals, the important role of sleep for extinction learning is well established.…”
Section: Discussionmentioning
confidence: 99%
“…However, some patients do not respond to this form of treatment, achieve only partial symptom remission, or fear often returns following initially successful therapy (Mystkowski et al 2002. Consequently, the development of novel and innovative approaches to increase therapeutic effectiveness is a primary challenge in current research on treatment of anxiety disorders (Ressler et al 2004;McNally, 2007;De Quervain, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…Finally, Rothbaum et al (2014) compared the effects of five VRET sessions augmented by D-cycloserine (DCS), which has been found to facilitate extinction in other fear-based disorders (Ressler et al, 2004), alprazolam, and placebo in a study with 156 OIF/OIF Veterans with PTSD. Although there were no differences in treatment outcome across medication conditions, with the exception of posttreatment and three-month follow-up CAPS scores indicating that the alprazolam group showed a higher rate of PTSD than the placebo group, PTSD symptoms significantly improved across all conditions at posttreatment and at the three-, six-, and 12-month follow-ups.…”
Section: Vret Research Outcomesmentioning
confidence: 99%
“…For example, administration of D-cycloserine (DCS), a partial agonist at the strychnine insensitive glycinebinding site of the NMDA receptor enhances extinction when administered either pre-or post-extinction (for review, see Richardson et al 2004). Moreover, DCS administration has been successfully used in recent clinical studies aimed at developing pharmacotherapeutic approaches to facilitating extinction of fear responses in anxiety disorders (Ressler et al 2004;Hofmann et al 2006). Whereas some extinction therapies used in clinical settings involve training in the presence of overt behavioral responses, other approaches are based on developing cognitive control over maladaptive behaviors, and this latter form of learning may not require overt responding during extinction training.…”
mentioning
confidence: 99%
“…Finally, pre-extinction training administration of DCS has been used successfully in conjunction with exposure therapy in the treatment of acrophobia (Ressler et al 2004) and social anxiety disorder (Hofmann et al 2006). The ability of DCS to enhance cognitive memory processes such as those putatively involved in latent extinction suggest that the drug may potentially have efficacy when used in conjunction with relatively "nonbehavioral" therapeutic strategies such as cognitive restructuring.…”
mentioning
confidence: 99%